Showing results (201-210 of 2,503) with videos related to
Sort By:
Pageof 251
Endocrine-Related Cancer|May 15, 2001
The epidermal growth factor receptor family as a central element for cellular signal transduction and diversificationN Prenzel, O M Fischer, S Streit, et al.Endocrine-Related Cancer|May 15, 2001
Cardiac metastasis from primary anaplastic thyroid carcinoma: report of three cases and a review of the literatureD Giuffrida, H GharibEndocrine-Related Cancer|September 21, 2019
Characterization of thyroid cancer driven by known and novel ALK fusionsFederica Panebianco, Alyaksandr V Nikitski, Marina N Nikiforova, et al.Endocrine-Related Cancer|September 28, 2019
Molecular imaging and radionuclide therapy of pheochromocytoma and paraganglioma in the era of genomic characterization of disease subgroupsDavid Taïeb, Abhishek Jha, Giorgio Treglia, et al.Endocrine-Related Cancer|July 17, 2019
How and when to use temozolomide to treat aggressive pituitary tumoursBen C WhitelawEndocrine-Related Cancer|March 11, 2011
Coxsackie and adenovirus receptor is a target and a mediator of estrogen action in breast cancerDavid Vindrieux, Ludovic Le Corre, Jer-Tsong Hsieh, et al.Endocrine-Related Cancer|May 10, 2011
The TORC1/TORC2 inhibitor, Palomid 529, reduces tumor growth and sensitizes to docetaxel and cisplatin in aggressive and hormone-refractory prostate cancer cellsGiovanni Luca Gravina, Francesco Marampon, Foteini Petini, et al.Endocrine-Related Cancer|May 10, 2011
In vitro transforming potential, intracellular signaling properties, and sensitivity to a kinase inhibitor (sorafenib) of RET proto-oncogene variants Glu511Lys, Ser649Leu, and Arg886TrpHugo Prazeres, Joana P Couto, Fernando Rodrigues, et al.Endocrine-Related Cancer|April 20, 2011
A critical evaluation of the role of aromatase inhibitors as adjuvant therapy for postmenopausal women with breast cancerThierry Petit, Patrick Dufour, Ian TannockPageof 251